Medpace Holdings Inc - Asset Resilience Ratio
Medpace Holdings Inc (MEDP) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Medpace Holdings Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2017)
This chart shows how Medpace Holdings Inc's Asset Resilience Ratio has changed over time. See MEDP equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Medpace Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Medpace Holdings Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.00K | 0.0% |
| Total Liquid Assets | $7.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Medpace Holdings Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Medpace Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Medpace Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Medpace Holdings Inc (2014–2017)
The table below shows the annual Asset Resilience Ratio data for Medpace Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $7.00K | $950.72 Million | -0.03pp |
| 2016-12-31 | 0.03% | $308.00K | $979.11 Million | -0.26pp |
| 2015-12-31 | 0.29% | $2.86 Million | $984.04 Million | +0.19pp |
| 2014-12-31 | 0.10% | $1.10 Million | $1.10 Billion | -- |
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medica… Read more